frontline therapy for egfr plus nsclc: osimertinib’s impact
Published 5 years ago • 88 plays • Length 5:18Download video MP4
Download video MP3
Similar videos
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
6:51
osimertinib as frontline therapy in egfr-positive nsclc
-
8:11
advances in frontline therapy for egfr nsclc
-
1:02
osimertinib for treatment of egfr lung cancer
-
1:23
dr. kujtan on frontline therapy for egfr-positive nsclc
-
1:15
osimertinib improves survival in egfr nsclc, poses new challenges for resistance
-
20:24
targeted treatment with egfr tkis: front line options
-
6:55
case 4: treating egfr nsclc after osimertinib
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
5:13
case 2: frontline therapy in egfr-mutated lung cancer
-
1:45
phase iii data support frontline osimertinib in egfr-mutant lung cancers
-
0:50
targeted option for non-small cell lung cancer #2023 #oncology #lungcancer
-
4:39
defining osimertinib’s value in treating egfr nsclc
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
1:21
fda approval of frontline osimertinib in frontline egfr-mutant nsclc
-
0:50
treating patients with egfr-mutant lung cancer with targeted therapies
-
3:27
egfr-mutant nsclc: selecting patients for osimertinib
-
5:24
case 4: egfr mutation analysis post-osimertinib
-
2:43
post-osimertinib treatment options for egfr nsclc - targeted therapies in lung cancer 2023